Literature DB >> 2989398

Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma.

T C Lynn, S M Tu, A Kawamura.   

Abstract

A total of 137 patients with biopsy-proved anaplastic epidermoid nasopharyngeal carcinoma (NPC) seen at the National Taiwan University Hospital from December 1971 through December 1973, were studied serologically before radiotherapy and during the follow-up period up to December 1982. A clear control study on 134 healthy patients or patients with diseases other than NPC was also done. EB virus-associated anti-VCA antibodies in both IgG and IgA classes were titrated by means of indirect immunofluorescent antibody method on two to six samples of serum from the patients during the follow-up study. When seropositive standard was set at 1:640 for anti-VCA/IgG and 1:40 for anti-VCA/IgA, the seropositive rates were 63.5 per cent and 81.1 per cent for NPC patients before treatment and 2.9 per cent and 2.2 per cent for the control respectively. The differences of seropositive rates between the patients and control were statistically highly significant, as chi 2 greater than 111, p less than 0.0005. At the completion of radiotherapy and during the following year, some reduction and fluctuation of seropositive rates were seen in both cured and recurrent patients. From the second year after radiotherapy and thereafter, the seropositive rates were 72 per cent-100 per cent for patients with recurrences and 17.6 per cent-30.8 per cent for cured patients. The differences were significant (chi 2 greater than 24.8, p less than 0.0005). Therefore, high titres of anti-VCA antibodies may coexist with cancer tissue in NPC patients. IgA class antibodies is slightly higher in sensitivity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989398     DOI: 10.1017/s0022215100097255

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

1.  Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator.

Authors:  T Yoshizaki; H Sato; S Murono; J S Pagano; M Furukawa
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

Review 2.  Emerging biomarkers in head and neck cancer in the era of genomics.

Authors:  Hyunseok Kang; Ana Kiess; Christine H Chung
Journal:  Nat Rev Clin Oncol       Date:  2014-11-18       Impact factor: 66.675

3.  Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.

Authors:  Shih-Hsin Chiu; Chung-Chun Wu; Chih-Yeu Fang; Shu-Ling Yu; Hui-Yu Hsu; Yen-Hung Chow; Jen-Yang Chen
Journal:  Oncotarget       Date:  2014-09-30

4.  Preliminary evaluation of a candidate international reference for Epstein-Barr virus capsid antigen immunoglobulin A in China.

Authors:  Hao Chen; Qiaohua Zhong; Xiaobin Wu; Yanling Ding; Qi Chen; Ning Xue; Yiwei Xu; Shulin Chen
Journal:  Infect Agent Cancer       Date:  2020-04-29       Impact factor: 2.965

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.